Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Yu-Yun Shao; Shen-Yung Wang; Shi-Ming Lin; Diagnosis Group,; Systemic Therapy Group

doi:10.1016/j.jfma.2020.10.031

Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

J Formos Med Assoc. 2021 Apr;120(4):1051-1060. doi: 10.1016/j.jfma.2020.10.031. Epub 2020 Nov 14.

Authors

Yu-Yun Shao¹, Shen-Yung Wang², Shi-Ming Lin³; Diagnosis Group,; Systemic Therapy Group

Collaborators

Kuan-Yang Chen⁴, Jeng-Hwei Tseng⁵, Ming-Chih Ho⁶, Rheun-Chuan Lee⁷, Po-Chin Liang⁶, Li-Ying Liao⁴, Kai-Wen Huang⁶, Jui-Ting Hu⁸, Ja-Der Liang⁶, Shen-Yung Wang⁹, Kwong-Ming Kee¹⁰, Chih-Lin Lin⁴, Shi-Ming Lin⁵, Chung-Kwe Wang¹¹, Sheng-Nan Lu¹⁰, Jing-Houng Wang¹⁰, Wei-Chen Lee⁵, Chien-Hung Chen¹², Chun-Jen Liu⁶, Yi-Hsiang Huang⁷, Chia-Chi Wang¹³, Tsang-En Wang⁹, Po-Heng Chuang¹⁴, Chia-Yen Dai¹⁵, Chiun Hsu⁶, Yu-Yun Shao⁶, San-Chi Chen⁷, Chia-Hsun Hsieh⁵

Affiliations

¹ Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
² Division of Gastroenterology and Hepatology, Department of Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
³ Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Division of Gastroenterology and Hepatology, Department of Medicine, MacKay Memorial Hospital, Taipei, Taiwan. Electronic address: lsmpaicyto@gmail.com.
⁴ Renai Branch, Taipei City Hospital, Taipei, Taiwan.
⁵ Chang Gung Memorial Hospital, Linkuo, Taiwan.
⁶ National Taiwan University Hospital, Taipei, Taiwan.
⁷ Taipei Veterans General Hospital, Taipei, Taiwan.
⁸ Cathay General Hospital, Taipei, Taiwan.
⁹ MacKay Memorial Hospital, Taipei, Taiwan.
¹⁰ Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
¹¹ Kang Ning Hospital, Taipei, Taiwan.
¹² National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.
¹³ Taipei Tzu Chi Hospital, Taipei, Taiwan.
¹⁴ China Medical University Hospital, Taichung, Taiwan.
¹⁵ Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

PMID: 33199101
DOI: 10.1016/j.jfma.2020.10.031

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid-enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities.

Keywords: Diagnosis; Guideline; Hepatocellular carcinoma; Surveillance; Systemic treatment.

Publication types

Practice Guideline

MeSH terms

Carcinoma, Hepatocellular* / diagnostic imaging
Carcinoma, Hepatocellular* / therapy
Contrast Media
Humans
Liver Neoplasms* / diagnostic imaging
Liver Neoplasms* / therapy
Magnetic Resonance Imaging
Taiwan
Ultrasonography

Substances

Contrast Media